What Is a GLP-1? How These Medications Work for Weight Loss

If you have heard about Ozempic, Wegovy, or Mounjaro, you have heard about GLP-1 medications — even if you did not know it by that name. What is a GLP-1, and why has this class of drugs become one of the most significant developments in modern medicine? Understanding the science behind these medications helps explain why they work so well, who benefits most, and what to expect if you decide to pursue treatment.

What Is a GLP-1? Understanding the Hormone

GLP-1 stands for glucagon-like peptide-1. It is a hormone naturally produced in your gut — specifically by specialized cells in the small intestine called L-cells — in response to eating. When you consume food, your gut releases GLP-1 into the bloodstream within minutes, triggering a cascade of effects that help regulate digestion, blood sugar, and appetite.

The problem is that natural GLP-1 has a very short half-life — it is broken down by an enzyme called DPP-4 in just two to three minutes. That is not long enough to produce the kind of sustained appetite suppression needed for meaningful weight loss. GLP-1 receptor agonists are synthetic versions of this hormone engineered to resist breakdown, allowing them to act for hours or even weeks.

The Gut-Brain Axis: How GLP-1 Reduces Appetite

One of the most important effects of GLP-1 is its action on the brain — specifically the hypothalamus, which regulates hunger and satiety. GLP-1 receptors are located throughout the central nervous system, and when activated, they send powerful signals that reduce appetite and increase feelings of fullness. This is why patients on GLP-1 medications often describe simply not feeling hungry, or feeling satisfied after much smaller amounts of food than usual.

This gut-brain connection — sometimes called the gut-brain axis — is a bidirectional communication system. Your digestive system does not just process food; it actively signals your brain about nutritional status, appetite hormones, and energy balance. GLP-1 is one of the key messengers in this system, and pharmaceutical GLP-1 agonists essentially amplify and extend these signals far beyond what your body produces naturally.

Gastric Emptying: Why You Feel Fuller Longer

Beyond the brain, GLP-1 also acts directly on the stomach, slowing the rate at which food moves from the stomach into the small intestine. This process — called gastric emptying — is significantly slowed by GLP-1 agonists. When food stays in your stomach longer, you feel full for extended periods after eating, which naturally reduces caloric intake without requiring willpower or calorie counting.

This slowing of gastric emptying is also responsible for some of the side effects people experience, particularly nausea, especially early in treatment. As the body adjusts over weeks, nausea typically diminishes significantly.

Insulin Regulation and Blood Sugar Control

GLP-1 has important roles in blood sugar regulation. It stimulates the pancreas to release insulin in response to elevated glucose — a process called glucose-dependent insulin secretion. Crucially, this insulin release is glucose-dependent, meaning GLP-1 agonists stimulate insulin only when blood sugar is high, not when it is already normal or low. This makes hypoglycemia far less of a concern compared to some other diabetes treatments.

GLP-1 also suppresses glucagon, a hormone that raises blood sugar by signaling the liver to release stored glucose. By lowering glucagon, GLP-1 agonists help maintain stable blood sugar throughout the day.

A Brief History of GLP-1 Medications

The history of GLP-1 drugs begins in the 1980s when researchers first identified the hormone and its role in insulin secretion. The first GLP-1 receptor agonist approved in the United States was exenatide (Byetta) in 2005, originally for type 2 diabetes. It required twice-daily injections, limiting convenience.

Liraglutide (Victoza) followed in 2010 with once-daily dosing and demonstrated cardiovascular benefits — a significant milestone. In 2014, the FDA approved liraglutide at a higher dose under the brand name Saxenda specifically for chronic weight management, marking the first GLP-1 approval for obesity treatment in adults.

The class evolved rapidly. Semaglutide (Ozempic) gained approval for type 2 diabetes in 2017, and the higher-dose version (Wegovy) was approved for chronic weight management in 2021 — producing average weight loss of approximately 15% of body weight in clinical trials. Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) arrived in 2022 and demonstrated even greater weight loss potential.

Comparing GLP-1 Medications: Semaglutide vs. Tirzepatide vs. Liraglutide

Semaglutide (Wegovy / Ozempic)

Semaglutide is a GLP-1 receptor agonist administered via once-weekly subcutaneous injection. The STEP clinical trial program demonstrated average weight loss of approximately 14.9% of body weight at the maximum approved dose over 68 weeks. Semaglutide is the most well-studied GLP-1 for weight loss and has shown cardiovascular benefits, with the SELECT trial demonstrating a 20% reduction in major adverse cardiovascular events in non-diabetic overweight adults with existing cardiovascular disease.

Tirzepatide (Zepbound / Mounjaro)

Tirzepatide represents the next generation of these medications. It is a dual agonist — activating both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is another gut hormone involved in metabolism and fat storage. By targeting both receptors simultaneously, tirzepatide has demonstrated superior weight loss in clinical trials — the SURMOUNT-1 trial showed average weight loss of approximately 20.9% at the highest dose, with many participants losing 25% or more.

Liraglutide (Saxenda)

Liraglutide was the first GLP-1 approved specifically for weight management. It requires daily injection and typically produces less weight loss than semaglutide or tirzepatide — averaging around 5–8% of body weight. It remains a valid option for patients who do not tolerate newer alternatives, but is generally considered less effective and convenient.

How These Medications Are Administered

Most GLP-1 medications for weight loss are administered via subcutaneous injection — into the fatty tissue just beneath the skin of the abdomen, thigh, or upper arm. These are small-gauge needles and are generally well tolerated. Semaglutide and tirzepatide are given once weekly, making adherence much easier than daily medications.

Doses are started low and increased gradually over several weeks — a titration period that allows the body to adjust and minimizes side effects. An oral form of semaglutide (Rybelsus) exists for diabetes management, though the injectable form is more commonly used for weight loss due to superior absorption.

What Results Can You Expect?

Results vary based on the individual, medication, dose, and lifestyle factors. General expectations based on clinical data:

• Weeks 1–4: Reduced appetite, early nausea, initial weight loss (1–5 lbs)
• Months 1–3: Steady weight loss, appetite substantially reduced, improved energy
• Months 3–6: Significant weight loss (often 5–10% of body weight), improved metabolic markers
• Months 6–18: Maximum weight loss plateau, often 15–20%+ of starting body weight with highest doses

Lifestyle changes — a protein-rich diet and regular physical activity — significantly amplify the results of GLP-1 medications. These medications work best as part of a comprehensive weight management program, not as a standalone intervention.

Side Effects and Safety Considerations

The most common side effects of GLP-1 medications are gastrointestinal — nausea, vomiting, diarrhea, and constipation. These are most pronounced during the titration phase and typically diminish as the body adapts. Eating smaller meals, avoiding fatty or spicy foods, and staying hydrated all help manage these symptoms.

Rare but serious concerns include pancreatitis and gallbladder disease. GLP-1 medications are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). A thorough medical evaluation is always performed before prescribing.

Who Is a Candidate for GLP-1 Therapy?

GLP-1 medications for weight loss are indicated for:

• Adults with a BMI of 30 or higher (obesity)
• Adults with a BMI of 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)

They are not appropriate for pregnant or breastfeeding individuals, those with certain thyroid or endocrine conditions, or those with a history of pancreatitis. A licensed provider evaluation ensures the medication is appropriate for your specific situation.

How to Get Started with GLP-1 Treatment

Accessing GLP-1 medications has become significantly easier through telehealth. Rather than waiting months for an in-person specialist appointment, you can complete a licensed provider evaluation online, often within days. At Truventa Medical, you complete a short health intake form, a licensed physician reviews your information, and if appropriate, a prescription is sent to a pharmacy — including compounding pharmacies offering substantially lower costs than brand-name options.

Compounded semaglutide and tirzepatide have made these medications accessible to a much broader population. While not covered by most insurance for weight loss indications, compounded medications can cost a fraction of brand-name Wegovy or Zepbound. If you are wondering whether a GLP-1 is right for you, a telehealth evaluation is the fastest and most convenient way to find out.